Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific
Solid Advanced Tumor
Betta Pharmaceuticals Co., Ltd.monoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Solid Advanced Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Part A: Ose-279 OSE Immunotherapeutics | Phase 1/2 | CCC |
OSE-279 OSE Immunotherapeutics | Phase 1/2 | CCC |
Ensartinib Betta Pharmaceuticals Co., Ltd. | Phase 1/2 | CCC |
ose2101 OSE Immunotherapeutics | Phase 1/2 | CCC |
Same molecule, other indications
Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →